OLIGOMETASTATIC PROSTATE CANCER (OMPC)
Clinical trials for OLIGOMETASTATIC PROSTATE CANCER (OMPC) explained in plain language.
Never miss a new study
Get alerted when new OLIGOMETASTATIC PROSTATE CANCER (OMPC) trials appear
Sign up with your email to follow new studies for OLIGOMETASTATIC PROSTATE CANCER (OMPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine combo aims to wipe out stubborn prostate cancer spots
Disease control Recruiting nowThis early-stage study is testing whether a new DNA vaccine, combined with an immunotherapy drug (nivolumab) and targeted radiation, can eliminate small areas of recurring prostate cancer that have spread. It's for men whose cancer has returned after prostate surgery but is limit…
Matched conditions: OLIGOMETASTATIC PROSTATE CANCER (OMPC)
Phase: PHASE1 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Targeted radiation zaps early prostate cancer spread, aims to delay harsh hormone therapy
Disease control Recruiting nowThis study is for men whose prostate cancer has returned and spread to a few locations after initial treatment. It aims to see if a targeted radiation drug (lutetium vipivotide tetraxetan) can better control the cancer and delay the need for hormone therapy compared to just monit…
Matched conditions: OLIGOMETASTATIC PROSTATE CANCER (OMPC)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC